Endoproteolysis of the β-amyloid precursor protein (APP) by β- and γ-secretases generates the toxic amyloid β-peptide (Aβ), which accumulates in the brain of Alzheimer's disease (AD) patients. Here, we established a novel approach to regulate production of Aβ based on intracellular expression of single chain antibodies (intrabodies) raised to an epitope adjacent to the β-secretase cleavage site of human APP. The intrabodies rapidly associated, within the endoplasmic reticulum (ER), with newly synthesized APP. One intrabody remained associated during APP transport along the secretory line, shielded the β-secretase cleavage site and facilitated the alternative, innocuous cleavage operated by α-secretase. Another killer intrabody with an ER retention sequence triggered APP disposal from the ER. The first intrabody drastically inhibited and the second almost abolished generation of Aβ. Intrabodies association with specific substrates rather than with enzymes, may modulate intracellular processes linked to disease with highest specificity and may become instrumental to investigate molecular mechanisms of cellular events.
Skip Nav Destination
Article navigation
14 March 2005
Report|
March 14 2005
β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide
Paolo Paganetti,
Paolo Paganetti
2Novartis Institutes for Biomedical Research Basel, Neuroscience Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
Search for other works by this author on:
Verena Calanca,
Verena Calanca
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Search for other works by this author on:
Carmela Galli,
Carmela Galli
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Search for other works by this author on:
Muriel Stefani,
Muriel Stefani
2Novartis Institutes for Biomedical Research Basel, Neuroscience Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
Search for other works by this author on:
Maurizio Molinari
Maurizio Molinari
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Search for other works by this author on:
Paolo Paganetti
2Novartis Institutes for Biomedical Research Basel, Neuroscience Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
Verena Calanca
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Carmela Galli
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Muriel Stefani
2Novartis Institutes for Biomedical Research Basel, Neuroscience Research, Novartis Pharma AG, CH-4002 Basel, Switzerland
Maurizio Molinari
1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
Correspondence to Maurizio Molinari: [email protected]
Abbreviations used in this paper: Aβ, amyloid β-peptide; AD, Alzheimer's disease; APP, β-amyloid precursor protein; BACE, β-site APP cleaving enzyme; HEK, human embryonic kidney 293; PS, PBS and permeabilized with 0.05% saponin.
Received:
October 08 2004
Accepted:
December 31 2004
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2005
J Cell Biol (2005) 168 (6): 863–868.
Article history
Received:
October 08 2004
Accepted:
December 31 2004
Citation
Paolo Paganetti, Verena Calanca, Carmela Galli, Muriel Stefani, Maurizio Molinari; β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide . J Cell Biol 14 March 2005; 168 (6): 863–868. doi: https://doi.org/10.1083/jcb.200410047
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement